LA
DGX icon

Lee Ainslie’s Quest Diagnostics DGX Stock Holding History

Lee Ainslie’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,756
Closed -$540K – 215
2026
Q1 		$540K Sell
2,756
-21,139
-88% -$4.11M 0.01% 218
2025
Q4 		$4.15M Buy
23,895
+5,717
+31% +$1.04M 0.04% 97
2025
Q3 		$3.46M Buy
+18,178
New +$3.23M 0.05% 116
2023
Q3 		– Sell
-8,046
Closed -$1.13M – 365
2023
Q2 		$1.13M Buy
8,046
+2,503
+45% +$345K 0.02% 154
2023
Q1 		$784K Buy
+5,543
New +$793K 0.02% 180
2021
Q2 		– Sell
-2,441
Closed -$313K – 714
2021
Q1 		$313K Buy
2,441
+1,813
+289% +$223K ﹤0.01% 435
2020
Q4 		$75K Buy
+628
New +$76.6K ﹤0.01% 602
2016
Q4 		– Sell
-37,510
Closed -$3.17M – 131
2016
Q3 		$3.17M Buy
+37,510
New +$3.15M 0.04% 56

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Lee Ainslie's DGX Position: Q2 2026 in Review

Lee Ainslie sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 2,756 shares — an estimated $540K sold.

Lee Ainslie first reported a position in DGX in Q3 2016 and held it in 8 quarters. The position peaked at $4.15M in Q4 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Lee Ainslie reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Lee Ainslie sold 2,756 Quest Diagnostics shares in Q2 2026, an estimated $540K.
  • Lee Ainslie first reported a position in Quest Diagnostics in Q3 2016 and held it in 8 quarters.
  • Lee Ainslie's Quest Diagnostics position peaked at $4.15M in Q4 2025.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.